fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Broad Markets Drifted Lower This Week While DKFG, JILL, & UPST Shined!

By John F. Heerdink, Jr.
Broad Markets Drifted Lower This Week

Happy Saturday All! I hope that you all are having a wonderful time with the family or with whatever suits you this weekend.

As for the week, the markets hit all time new highs early on & it seemed that the friendly ‘bunny hop’ market was moving along smoothly and here to stay just like it has been since the Fed start pumping copious amounts of money into the economy and subsequently into the market. However, around mid-week the markets quickly adopted a widespread cautious, if not negative tone, for the balance of the week. The downward and gloomy atmosphere was spearheaded by the reports of  ‘evil’ interest rate spikes that continued in the face of Jerome Powell’s FOMC statement. In the statement, the Fed forecasted stronger economic growth & moved their ‘real’ GDP numbers from 4.2% to 6.5% while confessing that they see inflation rising to some degree in 2021, but also reiterated that they intend to keep interest rates at near-zero levels through 2023. In concert, but countering these so-called good Fed vibes, we also received negative news from Europe, which confirmed a third wave of COVID-19 growth fueled by variants and a lack of progress regarding vaccine accumulation & distribution that was led to new shutdowns & subsequently growth concerns blossomed in the minds of investors and ignited algorithms alike.

To put icing on the cake Friday, the Fed confirmed it would allow the temporary Supplementary Leverage Ratio (“SLR”) exemption, something that most have no idea existed, expire on March 31 as they needed to review the situation due to concerns it is no longer functioning as intended, which in turn increased the level of uncertainty and fears in the markets. The combination of these headlines led to the downward pressure on the markets, especially regarding anything ‘growth oriented’ i.e. the influential information tech which dropped 1.4%. In addition, added pressure surfaced across cyclical names i.e. the energy sector which cascaded 7.7% wk/wk as oil pulled back to close at $61.45/bbl (still high in many circles), the financials sector which fell 1.7% wk/wk, & the real estate sector which was also off 1% wk/wk. 

In turn the the indices ended down across the board as follows: The Dow ended at 32,627.97 (-.5%, wk/wk) (+6.6% YTD), the Nasdaq Composite closed at 13,319.86 (-8%, wk/wk ) (+2.5% YTD) & the S&P 500 closed at 3,913.10 (-.8%, wk/wk) (+4.2% YTD) & Russell 200o had the worse week as it ended at 2,352.79 (-2.8%, wk/wk but still up +15.8% YTD.

Interest rates ended as follows: the 2-yr yield rose 2 basis points to end at .16%, the 10-year yield rose 9 basis points for the second week in a row to close at 1.73%, & the 30-year yield closed at 2.43% up from 2.38%.

The U.S. Dollar Index edged higher from 91.63 last week to close at 91.86 this week.

THE WEEK’s “MACRO”

On Monday, the macroeconomic schedule produced the Empire State Manufacturing Survey report which confirmed a rise to 17.4 in March. On Tuesday, the Total retail sales report confirmed a drop by 3% month/month in February. This was countered somewhat by the the Total sales report which confirmed a rise by 7.6% & when you exclude autos it jumped 8.3%. The Total industrial production report confirmed a 2.2% decline month/month in February. The capacity utilization rate fell to 73.8% most like a result of in climate weather that was widespread during this period. The NAHB Housing Market Index report dropped to 82 in March. The Business inventories report confirmed a rise by .3% in January. The Import prices report shoed a rise by 1.3% in February & Export prices rose by 1.6% in February. On Wednesday, The Total retail sales report confirmed a drop by 3% month/month in February. This was countered somewhat by the the Total sales report which confirmed a rise by 7.6% & when you exclude autos it jumped 8.3%. The Total industrial production report confirmed a 2.2% decline month/month in February. The capacity utilization rate fell to 73.8% most like a result of in climate weather that was widespread during this period. The NAHB Housing Market Index report dropped to 82 in March. The Business inventories report confirmed a rise by .3% in January. The Import prices report shoed a rise by 1.3% in February & Export prices rose by 1.6% in February. On Thursday, the Initial jobless claims report for the week ending March 13 confirmed a rise by 45k to 770k & the continuing claims report for the week ending March 6 showed a drop by 18k to 4.124M. The Conference Board’s Leading Economic Index report confirmed a rise by .2% month/month in February. 

Next week, we will receive the Existing Home Sales report for February, the Final GDP growth figure, the PMI composite, and the PCE deflator report.  

TECH HIGHLIGHTS

The ever so popular FAANG’s ended down across the board except for Facebook that jumped 4% on Friday CEO Mark Zuckerberg made positive comments about how Apple’s privacy rule changes may help Facebook, The FAANG’s ended the week as follows: Apple (AAPL) shares closed at $119.99 down from last Friday’s close of $121.03, Amazon (AMZN) closed at $3,074.96 up from last Friday’s close of $3,089.49, Alphabet (GOOG) closed at $2,043.20 down from last Friday’s close of $2,061.92, Facebook (FB) closed at $290.11 up nearly $26/share from last Friday’s close of $264.40 & Netflix (NFLX) closed at $512.18 down from last Friday’s close of $518.02/share. 

Leading EV car maker Tesla (TSLA) slipped to close at $654.87 & down from the $693.73 close last week.

The much traded and Reddit followed Gamestop (GME) closed at $200.27 down from the close $264.50 last Friday.

One of the extremely positive stories came Thursday as Upstart Holdings, Inc. (NASDAQ: UPST), a leading artificial intelligence (AI) lending platform, which rose 89.32% to close at $115.09 then legged on up to close at $125.28 on Friday. On Thursday, Upstart announced that it had entered into a definitive agreement to acquire Prodigy Software, Inc., a provider of cloud-based automotive retail software. Dave Girouard, co-founder and CEO of Upstart stated, “While Amazon and Shopify have modernized the online shopping experience, the auto industry has been left behind. Upstart is on a path to reduce the cost of auto financing, and we can accelerate this opportunity with a modern multi-channel purchase experience. Auto retail is among the largest buy-now-pay-later opportunities, and together with Prodigy, we aim to help dealers create a seamless and inclusive experience worthy of 2021.” Michia Rohrssen, CEO of Prodigy, said, “Our mission has always been to build the world’s best car buying experience, and for the majority of buyers today, that experience includes financing their vehicle. Upstart’s demonstrably better lending technology will enable us to deliver more affordable and transparent auto loans to millions of consumers through our dealer network.” Stay tuned in to this story as approximately $1 trillion of cars are sold in the US, and most of them are financed and thus they may continue to develop as purchasing a car consistently ranks among the worst consumer experiences, with less than 1% of buyers satisfied with the current process.

ACROSS THE DOW 30

Nike (NKE) reported earnings after the close & beat earnings estimates on Thursday while missing on revenue. Q3 reported revenues were $10.4 billion, up 3 percent compared to prior year and down 1 percent on a currency-neutral basis led by Greater China reported revenue growth of 51 percent. NIKE Direct sales were $4 billion, up 20 percent on a reported basis, and up 16 percent on a currency-neutral basis. NIKE Brand digital sales increased 59 percent, or 54 percent on a currency-neutral basis, with strong double-digit increases in all geographies. North America reported revenue declined 10 percent due to supply chain challenges, including global container shortages and U.S. port congestion, impacting the flow of inventory and timing of wholesale shipments.

Disney Schedules Release Of Fiscal Q2 Results On May 13

Walmart Collaborating With American Fashion Designer Brandon Maxwell

The Walt Disney Company’s (DIS) Disney+ streaming program has surpassed 100 million new subscribers, reaching the 9-digit subscriber mark in only 16 months of operations as its users continued to grow during the pandemic. The news was welcomed by Disney CEO Bob Chapek during the company’s annual shareholder meeting this week. The latest growth also marks an increase from the 94.2 million subscribers Disney last reported less than one month ago.

JPMorgan (JPM) Widens Recruitment Program To Include More Black College Students 

Boys & Girls Clubs Of America Working With Salesforce (CRM) To Deliver A Streamlined & Personalized Experience

BIOTECH

iShares Nasdaq Biotechnology ETF (IBB) closed at $155.89 moves up from last week’s close of $154.75. The NYSE ARCA Biotech Index (^BTK) closed at 5,579.59 up again from last week’s close of 5,547.85. 

Reportedly, AIFA, Italy’s medicines agency has approved the use of the single-dose COVID-19 vaccine produced by Johnson & Johnson (JNJ) following approval from the European drugs regulator last week. The J&J’s vaccine approval marks fourth to be allowed for use in the European Union after vaccines from Pfizer-BioNTech, AstraZeneca-Oxford University, and Moderna received approval for usage for those over 18 years of age.

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK-Engager Bispecific antibodies, announced today two agreements for R&D and manufacturing operations in Massachusetts and Puerto Rico that will accelerate the company’s Universal iPSC NK cells towards clinical trials beginning in Q4 2021 and gene-edited iPSC CAR-NK cells by 2022. Cytovia will move into state-of-the-art laboratory space at the ABI-LAB facility in Natick, MA in March, and has started recruiting R&D and process development personnel to its existing team. Cytovia’s existing cell therapy operation under the New York Stem Cell Foundation and antibody GMP manufacturing with STC Biologics will continue. In a parallel investment, Cytovia signed a long-term joint collaboration manufacturing and operations agreement with BioSciencesCorp to integrate Cytovia’s manufacturing processes within an existing 95,000 ft2 cGMP facility, including more than 40,000 ft2 of clean-room and biomanufacturing, located in Aguadilla, Puerto Rico. The company will recruit manufacturing personnel beginning in summer 2021. “We’re excited to rapidly expand our R&D team with the best talent in the Boston area. The combination of advanced laboratory space and cost-effective cGMP manufacturing capability represents a highly significant milestone as Cytovia’s NK off-the-shelf cell therapies and bispecific products accelerate towards the market,” said Wei Li, Chief Scientific Officer of Cytovia Therapeutics “The integration of Cytovia’s two new facilities is designed to allow the company to take each of our products rapidly and seamlessly into clinical and commercial production.”

GOLD & SILVER MARKETS

Gold prices closed at $1746 up from the $1,728/oz. close last week. This Friday silver prices closed at $26.33/oz. up from the $26.01/oz. close last Friday.

Recently, Phillips S. Baker, Jr., President, and CEO of Hecla Mining Company (NYSE: HL) ($6.50, flat wk/wk) discussed “The Silver Squeeze” while addressing questions from the Tribe Public where he offered valuable insights on silver prices throughout history and the recent volatility that helped move silver related stocks & silver prices. Please view the event video here now. 


JILL – FDX – DKNG

J.Jill, Inc. (NYSE: JILL), a premier omnichannel retailer and nationally recognized women’s apparel brand committed to delighting customers with great wear-now product, annihilations, jumped to a new 52-week high of $9.69 up from the $4.12 level a week ago Thursday prior to closing at $9.20 on Friday. On Tuesday,  Jill reported its financial results for the fourth quarter and fiscal year ended January 30, 2021. Claire Spofford (kn0wn for turnarounds), President and Chief Executive Officer of J.Jill, Inc. stated, “Fiscal 2020 was an unprecedented year for retail given the impact of the COVID-19 pandemic. Despite these challenges, through deliberate and aggressive actions, the teams positioned us to end the year with enhanced financial stability, a more nimble cost structure, and cleaner inventory balances. Our fourth quarter results reflect these actions as well as continued progress as we again delivered sequential topline improvement compared to our prior quarter. As we look ahead, we will continue to take disciplined and strategic actions to strengthen the foundation of our operating model to better realize the potential of the J Jill brand and business.” Here’s the balance of the release.

FedEx (FDX) closed at $279.58, +6.1% on Friday after an earnings beat.

DraftKings Inc. (DKNG) closed at an all-time closing high at $71.98, +6.46% Friday as online gambling is on the rise & may see an increase during March madness that kicked off this week. Who’s your pick to win it all? With my childhood favorites, IU’s Hoosiers, once again on the sideline, I am tossing a coin between Gonzaga and Illinois to take it all. 

TRADING NEXT WEEK 

We are back to 5-trading sessions again next week. 



 
VP WATCHLIST UPDATES

Please consider reviewing our complete VP Watchlist here that includes a brief list of highlighted companies that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily. Below is an update for five of the smaller companies from the VP Watchlist. 

  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed at $18.33 up from the $14.84 close from 3 weeks ago. Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.
    • This week, Chinook announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor. “The initiation of the phase 3 ALIGN Study is an important milestone for Chinook as we advance our pipeline of programs for rare, severe chronic kidney diseases,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan has been studied in over 5,300 diabetic kidney disease patients in the phase 2 RADAR and phase 3 SONAR studies, demonstrating rapid, sustained proteinuria reductions of approximately 30 to 35 percent as well as improved eGFR. Importantly, treatment with atrasentan also resulted in a reduction in clinical outcomes of development of end-stage kidney disease and doubling of serum creatinine. We look forward to exploring the proteinuria-lowering, anti-inflammatory and anti-fibrotic effects of atrasentan in patients with IgA nephropathy, a serious progressive disease for which there are no approved therapies.”
    • On March 1, Chinook and and Evotec SE announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinook’s clinical and preclinical pipeline. “We are excited to embark on this strategic collaboration with Evotec, the leading drug discovery alliance and development partner in nephrology,” said Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine at Chinook. “Gaining access to the NURTuRE cohort study and other proprietary patient biobanks, along with Evotec’s multi-omics integration platform, will enable us to define the molecular drivers of kidney diseases, identify novel targets for drug development in selected patient sub-populations and continue to build the foundation for our precision medicine approach. With a focus on comprehensive molecular disease classification, combined with prospective clinical outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations.”
    • Recently, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.
    • I will be hosting Chinook’s President & CEO Eric Dobmeier at our sister organization Tribe Public’s Presentation and Q&A event, Thursday, April 15th titled “Revolutionizing The Treatment of Kidney Disease.”You can register for FREE today at KDNY.TribePublic.com. Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.
    • Chinook has well-funded development programs with participation in a $115 million private placement financing concurrent with the close of a merger with Aduro Biotech in Q4 2020 from top-tier healthcare investors including, EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and others.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $90.29/share up from $893.65 last Friday but still shy of its recently achieved a new all-time high of $121.16. We started with this one folks over 3 years ago when it was in the $3 range.
    • Fate announced that the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 5:00 p.m. ET to report its fourth quarter and full year 2020 financial results and provide a corporate update. Learn more here. 
    • Recently, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab. Our recent Phase 1 clinical data with FT516 in combination with rituximab, which demonstrate the potential of our novel hnCD16 Fc receptor to potentiate ADCC and drive complete responses, support our belief that the multi-antigen targeting functionality of FT596 may offer best-in-class potential for patients with B-cell malignancies.” 
    • We have made another investment in a private company called Cytovia Therapeutics that owns its own NK cell platform that some investors are calling “FATE 2.0”. They are seeking to go next year in Q2/Q3 as there is room in the markets for another NK cell company. Their website is www.cytoviatx.com.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.78 down nicely from the $2.91/share close last Friday and is trading 25.14M shares a day.
    • Last week, Atossa announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient. READ today’s story.
    • Recently Atossa announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. Steven Quay, M.D., Ph.D., Atossa’s President and CEO stated, “The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301. We recently received input from the FDA on this program and based in part on that input, we are now preparing to conduct an additional pre-clinical study, which we expect to start this quarter. Following that, we expect to apply to the FDA to commence a Phase 2 study here in the United States.” Learn more here.
    • Atossa recently announced updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen. “To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator. “This patient, like many breast cancer patients, was reluctant to take tamoxifen because of the well-documented side effects associated with that drug and because she lacked the proper liver enzymes to properly metabolize tamoxifen. We are very encouraged by this patient’s experience with our Endoxifen over the past two years. Her experience serves as a model for ongoing development efforts,” commented Steve Quay, Ph.D., M.D., Atossa’s President and CEO.
    • Atossa raised ~$81M in gross proceeds between Dec. 2020 and Jan. 2021 affording the company a significant development runway and many more options to be considering. 
    • Atossa is seeking in the near term to get an FDA nod to move into a Phase 2 trial with its nasal spray COVID-19 therapy.
  •  
  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $4.71/share this Friday.
    • This week, INVO announced the signing of a 50/50 joint venture agreement in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD, to open the first Joint Venture INVO-exclusive clinic in the United States.
    • Last week, after the close INVO announced that they has agreed to an amendment of their agreement with Ferring Pharmaceuticals that provides for an increase in the number of INVO company-owned US-based clinics initially allowable under the agreement and removes certain geographical restrictions. The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021. READ STORY.
    • With increased support and flexibility from Ferring I am expecting INVO management to announce 1-2 agreements regarding the opening of INVOcell only US clinics still in Q1 per the CEO’s shareholder letter. PLEASE READ IT HERE.
    • Last week, INVO announced the Company has received approval by COFEPRIS to import INVOcell into Mexico. In late 2020, INVO Bioscience established a joint venture focused on establishing fertility centers dedicated to offering INVOcell, with the initial center, called Positib Fertility, to be located in the city of Monterrey, Mexico. Steve Shum, CEO of INVO Bioscience, commented, “We are extremely pleased to have received approval by COFEPRIS to begin importing INVOcell into Mexico. This was a key step in the process to open our first joint venture owned clinic in the large and growing Mexico market for infertility services. Our internal team along with our JV partners have and continue to work aggressively and with a relentless focus to bring the INVOcell treatment option to the many patients in need of care within Mexico.”
    • Recently, INVO announced it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.



  • Shares of NeuBase Therapeutics (NBSE) closed trading this week at $8.47/share after recently establishing a new all time high of $12.89. Recently, Neubase reported its financial results for the three-month period ended December 31, 2020. Review the story here.
    • Oppenheimer’s analyst Hartaj Singh has reiterated his OUTPERFORM Rating and his Price Target of $17.
    • NBSE recently announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc. The technology has demonstrated the ability to resolve disease in genetic models of several human indications. The acquisition was reported to bolster NeuBase’s capabilities and reinforces the Company’s position as a leader in the field of genetic medicine. Read the complete story.
    • The company expects to successfully negotiate a corporate licensing deal of some kind prior to the one-year anniversary of their April, 2020 equity financing as stated in a recent interview.
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

Please review our complete VP Watchlist now that includes 10 highlighted companies. The pages will allow you to learn more and keep up with these companies daily.

QUOTE OF WEEK

“Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Investing & Inspiration

  1. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  2. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  3. “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  4. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  5. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  6. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  7. “In investing, what is comfortable is rarely profitable.” — Robert Arnott
  8. “Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
  9. “No Price is too low for a bear or too high for a bull.” — Anonymous
  10. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
  11. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  12. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  13. “If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
  14. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  15. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  16. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  17. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  18. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  19. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  20. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  21. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  22. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  23. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  24. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  25. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  26. “We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
  27. “Never test the depth of the river with both of your feet.” – Warren Buffet
  28. “Know what you own, and know why you own it.” – Peter Lynch
  29. “Liquidity is only there when you don’t need it.” -Old Proverb
  30. “There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
  31. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  32. Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  33. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  34. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  35. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  36. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
  37. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  38. “Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
  39. “Remember that the stock market is a manic depressive.”  – Warren Buffett
  40. “An investment in knowledge pays the best interest.” – Benjamin Franklin
  41. “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  42. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  43. “The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  44. “If all the economists were laid end to end, they’d never reach a conclusion.
    -George Bernard Shaw
  45. “The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
  46. “In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
  47. “In investing, what is comfortable is rarely profitable.” -Robert Arnott
  48. “The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
  49. “How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
  50. “Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
  51. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  52. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  53. “I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
  54. “Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers

Videos

Please consider viewing these interesting videos: